Asset Details
Do you wish to reserve the book?
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Do you wish to request the book?
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
2015
Overview
Weekly doses of an antisense inhibitor of apolipoprotein C-III (APOC3) in persons with severe or uncontrolled hypertriglyceridemia resulted in a reduction in APOC3 and triglyceride levels at the end of 13 weeks.
Elevated triglyceride levels are associated with several pathologic conditions, including insulin resistance, the metabolic syndrome, diabetes, cardiovascular disease, and hereditary disorders, such as the familial chylomicronemia syndrome, familial combined hyperlipidemia, and familial hypertriglyceridemia.
1
,
2
Patients with triglyceride levels above 2000 mg per deciliter (22.6 mmol per liter), measured at the peak of abdominal pain, are at high risk for pancreatitis.
3
,
4
Current guidelines from the Endocrine Society and the European Atherosclerosis Society recommend that fasting triglyceride levels should be maintained at values below 1000 mg per deciliter (11.3 mmol per liter) or 10 mmol per liter, respectively, to prevent intermittent . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Apolipoprotein C-III - antagonists & inhibitors
/ Apolipoprotein C-III - biosynthesis
/ Apolipoprotein C-III - blood
/ Dose-Response Relationship, Drug
/ Fasting
/ Female
/ Fibric Acids - therapeutic use
/ Humans
/ Hypertriglyceridemia - blood
/ Hypertriglyceridemia - drug therapy
/ Male
/ Oligonucleotides - administration & dosage
/ Oligonucleotides - adverse effects
/ Oligonucleotides - pharmacology
/ Patients
